LEADER 06967nam 2202041z- 450 001 9910404087003321 005 20231214133603.0 010 $a3-03928-639-0 035 $a(CKB)4100000011302268 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/58186 035 $a(EXLCZ)994100000011302268 100 $a20202102d2020 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aRenal Cell Carcinoma 210 $cMDPI - Multidisciplinary Digital Publishing Institute$d2020 215 $a1 electronic resource (500 p.) 311 0 $a9783039286386 330 $aRenal cancer is a health problem of major concern worldwide. Although tyrosine kinase inhibitors and immune check-point blockade treatments, alone or in combination, are giving promising results, failures are quite frequent due to intratumor heterogeneity and to the acquisition of drug resistance. The spectrum of renal cell carcinoma subtypes is wide. Up to 70?80% of renal tumors are clear cell renal cell carcinomas, a clinically aggressive tumor subtype linked to VHL gene inactivation. Next in frequency, the papillary renal cell carcinoma category encompasses an intricate puzzle of classic and newly described entities with poorly defined limits, some of them pending definite clarification. Likewise, the chromophobe?oncocytoma duality, the so-called hybrid tumors and oncocytic neoplasms, remain to be well profiled. Finally, a growing list of very uncommon renal tumors linked to specific molecular signatures fulfill the current portrait of renal cell neoplasia. This Special Issue of Cancers regards RCC from very different perspectives, from the intimate basic mechanisms governing this disease to the clinical practice principles of their diagnoses and treatments. The interested reader will have the opportunity to contact with some of the most recent findings and will be updated with excellent reviews. 606 $aRenal cell carcinoma 606 $aKidneys$xCancer 610 $aN-glycomapping 610 $aSMAD proteins 610 $apatient survival 610 $apro-IL-1? 610 $asurvival prediction 610 $ainflammation markers 610 $atumor migration 610 $aprognostic factors 610 $apractical approach 610 $acircular RNAs in a clinico-genomic predictive model 610 $aglycomarkers 610 $areview 610 $anephrectomy 610 $auric acid 610 $aVEGF inhibitors 610 $ametabolic reprogramming 610 $acollecting duct carcinoma 610 $acurcumin 610 $ametabolome profiling 610 $aidentification of circular RNAs 610 $aIL-2 610 $aexperimental validation of circular RNA 610 $aRaf/MEK/ERK 610 $aHOT 610 $aPI3K/Akt/mTOR 610 $apentose phosphate pathway 610 $akidney cancer 610 $aLOT 610 $amutation 610 $aRCC 610 $apolybromo-1 610 $apale cell 610 $aMMP-9 610 $agene expression 610 $arecurrence free survival 610 $achromosomal loss 610 $aIL-1? 610 $achronic kidney disease 610 $aglutathione transferase omega 2 610 $alabel-free 610 $aglutathione transferase omega 1 610 $aemerging entity 610 $acopy number alteration 610 $aFOXO3 610 $apredictive role 610 $atumor slice culture 610 $atyrosine kinase inhibitors 610 $aPPP 610 $aESC 610 $aCDKN1A expression 610 $ametastasis 610 $aPD-L1 610 $adiagnostic and prognostic markers 610 $aEVI1 610 $acopy number loss 610 $aRNA sequencing 610 $aNK cells 610 $aglutathione metabolism 610 $aclear cell renal cell carcinoma 610 $arenal cell cancer 610 $aproliferation 610 $aeosinophilic variant 610 $aXp11 translocation renal cell carcinoma 610 $aprognosis 610 $ainvasion 610 $aimmune infiltration 610 $aIL4R? 610 $aFISH 610 $a11) translocation renal cell carcinoma 610 $atumor microenvironment 610 $ametabolome 610 $ahyperosmolality 610 $atoxicity 610 $aALK 610 $adrug sensitivity 610 $at(6 610 $acopy number analysis 610 $aurine 610 $agenetic association 610 $apolymorphism 610 $asolute carrier proteins 610 $akidney 610 $ametastatic ccRCC 610 $amolecular genetic features 610 $arecurrence-free survival 610 $achromophobe renal cell carcinoma 610 $aunclassified renal tumor 610 $aoverall survival 610 $amTOR inhibitors 610 $amTOR 610 $aJAK2 610 $avon Hippel-Lindau 610 $amiR-155-5p 610 $aglycoproteomics 610 $aPBRM1 610 $amiR-133b 610 $asurvival 610 $aTFE3 610 $aTFEB 610 $aoncocytic renal tumor 610 $aimmune checkpoint inhibitors 610 $abiomarker 610 $aMMP10 610 $aTCGA 610 $aghrelin 610 $aEMT like 610 $acheckpoint inhibitors 610 $aMiT family translocation renal cell carcinoma 610 $agene signature 610 $asarcomatoid 610 $atransforming growth factor beta 610 $aclear cell Renal Cell Carcinoma 610 $atumor adhesion 610 $arenal cancer 610 $aunclassified renal cell carcinoma 610 $aPapillary renal cell carcinoma (pRCC) 610 $amiR-146a-5p 610 $arenal cell 610 $aeverolimus 610 $aintegrins 610 $acytoreductive nephrectomy 610 $aimmunotherapy 610 $apredictive factors 610 $aimmunohistochemistry 610 $aMTA2 610 $aIL13R?1 610 $atargeted therapy 610 $aintratumour heterogeneity 610 $aaurora A 610 $aTCA cycle 610 $aAMP-activated protein kinases 610 $acancer-specific survival 610 $aprogrammed death-ligand 1 610 $aefficacy 610 $arenal cell carcinoma 610 $aanaplastic lymphoma kinase rearrangement 610 $aTFEB-amplified renal cell carcinoma 610 $astatins 610 $acancer immunotherapy 610 $amicroRNA 610 $anew entity 610 $aproteome profiling 615 0$aRenal cell carcinoma. 615 0$aKidneys$xCancer. 700 $aLo?pez$b Jose? I$4auth$00 906 $aBOOK 912 $a9910404087003321 996 $aRenal Cell Carcinoma$92809988 997 $aUNINA